elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q28445037-E4A1A89F-574B-4B6E-A3CE-5527A8FBB965
Q28445037-E4A1A89F-574B-4B6E-A3CE-5527A8FBB965
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28445037-E4A1A89F-574B-4B6E-A3CE-5527A8FBB965
KRAS MUTATION
P3354
Q28445037-E4A1A89F-574B-4B6E-A3CE-5527A8FBB965
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28445037-E4A1A89F-574B-4B6E-A3CE-5527A8FBB965
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a153437ff06aae178f253b777bb904b507717f02
P1310
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
P2175
colorectal cancer
P4271
CIViC 2-star trust rating
P459
CIViC evidence level C
P3354
refametinib